114 related articles for article (PubMed ID: 37097644)
61. Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
Fahmawi Y; Smith C; Grimm L; Khullar S; Rider P; Hunter J; Iliff G; Mneimneh W; Roveda K; Wang B; Prodduturvar P; Alkharabsheh O; McCormick B; Mizrahi M; Khushman M
Clin Colorectal Cancer; 2020 Dec; 19(4):e281-e287. PubMed ID: 32694005
[TBL] [Abstract][Full Text] [Related]
62. Efficacy and safety of wait and see strategy versus radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy: a meta-analysis.
Zhao GH; Deng L; Ye DM; Wang WH; Yan Y; Yu T
World J Surg Oncol; 2020 Aug; 18(1):232. PubMed ID: 32862826
[TBL] [Abstract][Full Text] [Related]
63. Instrumental clinical restaging, pathological evaluation, and tumor regression grading: how to assess the response to neoadjuvant chemoradiotherapy for rectal cancer.
Benzoni E; Terrosu G; Intersimone D; Milan E; Chiaulon G; Bresadola V; Sacco C; Sattin E; Bresadola F; Avellini C
Int J Colorectal Dis; 2007 Jan; 22(1):7-13. PubMed ID: 16538492
[TBL] [Abstract][Full Text] [Related]
64. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
65. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
66. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
[TBL] [Abstract][Full Text] [Related]
67. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
68. Locally advanced rectal cancer: Preliminary results of rectal preservation after neoadjuvant chemoradiotherapy.
Vaccaro CA; Yazyi FJ; Ojra Quintana G; Santino JP; Sardi ME; Beder D; Tognelli J; Bonadeo F; Lastiri JM; Rossi GL
Cir Esp; 2016 May; 94(5):274-9. PubMed ID: 26980259
[TBL] [Abstract][Full Text] [Related]
69. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.
Zhang LN; Xiao W; OuYang PY; You K; Zeng ZF; Ding PR; Pan ZZ; Xu RH; Gao YH
Tumour Biol; 2015 Sep; 36(10):8213-9. PubMed ID: 25994571
[TBL] [Abstract][Full Text] [Related]
70. Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Dreussi E; Pucciarelli S; De Paoli A; Polesel J; Canzonieri V; Agostini M; Friso ML; Belluco C; Buonadonna A; Lonardi S; Zanusso C; De Mattia E; Toffoli G; Cecchin E
Oncotarget; 2016 Apr; 7(15):19781-93. PubMed ID: 26934318
[TBL] [Abstract][Full Text] [Related]
71. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
72. Significance of HPV infection and genic mutation of APC and K-ras in patients with rectal cancer.
Sun ZQ; Wang HJ; Zhao ZL; Wang QS; Fan CW; Fang F
Asian Pac J Cancer Prev; 2013; 14(1):121-6. PubMed ID: 23534709
[TBL] [Abstract][Full Text] [Related]
73. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
[TBL] [Abstract][Full Text] [Related]
74. [Pathological insights of radiotherapy-related damage to surgical margin after preoperative radiotherapy in patients with rectal cancer].
Zhong QH; Wu PH; Qin QY; Kuang YY; Ma TH; Wang HM; Zhu YX; Chen DC; Wang JP; Wang L
Zhonghua Wai Ke Za Zhi; 2017 Jul; 55(7):507-514. PubMed ID: 28655079
[No Abstract] [Full Text] [Related]
75. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
76. A prognostic nomogram for stage II/III rectal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgical resection.
Lin Y
BMC Surg; 2022 Jul; 22(1):256. PubMed ID: 35787802
[TBL] [Abstract][Full Text] [Related]
77. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
78. NEOADJUVANT THERAPY AND SURGERY FOR RECTAL CANCER. Comparative study between partial and complete pathological response.
Andrade VA; Coy CS; Leal RF; Fagundes JJ; Martinez CA; Ayrizono Mde L
Arq Gastroenterol; 2016; 53(3):163-8. PubMed ID: 27438421
[TBL] [Abstract][Full Text] [Related]
79. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
80. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Lin S; Lai H; Qin Y; Chen J; Lin Y
Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
